News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Move to increase affordability and accessibility for heart failure patients across the country
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)